schliessen

Filtern

 

Bibliotheken

Cover Image

The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer

Clinicians have traditionally used clinicopathological (CP) factors to determine locoregional recurrence (LR) risk of breast cancer and have generated the IBTR! nomogram to predict the risk of ipsilateral breast tumor recurrence (IBTR). The 21-gene recurrence score (RS) assay was recently correlated... Full description

Journal Title: SpringerPlus 2015-01-30, Vol.4 (1), p.36-36
Main Author: Thaker, Nikhil G
Other Authors: Hoffman, Karen E , Stauder, Michael C , Shaitelman, Simona F , Strom, Eric A , Tereffe, Welela , Smith, Benjamin D , Perkins, George H , Huo, Lei , Munsell, Mark F , Pusztai, Lajos , Buchholz, Thomas A , Woodward, Wendy A
Format: Electronic Article Electronic Article
Language: English
Subjects:
21-gene recurrence score
Breast Cancer
gene recurrence score
Humanities and Social Sciences
IBTR
Ipsilateral breast tumor recurrence
Local recurrence
Medicine
Molecular profiling
multidisciplinary
Oncotype Dx
Research
Science
Science (multidisciplinary)
Publisher: Cham: Springer International Publishing
ID: ISSN: 2193-1801
Link: https://www.ncbi.nlm.nih.gov/pubmed/25674496
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_crossref_primary_10_1186_s40064_015_0840_y
title: The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
format: Article
creator:
  • Thaker, Nikhil G
  • Hoffman, Karen E
  • Stauder, Michael C
  • Shaitelman, Simona F
  • Strom, Eric A
  • Tereffe, Welela
  • Smith, Benjamin D
  • Perkins, George H
  • Huo, Lei
  • Munsell, Mark F
  • Pusztai, Lajos
  • Buchholz, Thomas A
  • Woodward, Wendy A
subjects:
  • 21-gene recurrence score
  • Breast Cancer
  • gene recurrence score
  • Humanities and Social Sciences
  • IBTR
  • Ipsilateral breast tumor recurrence
  • Local recurrence
  • Medicine
  • Molecular profiling
  • multidisciplinary
  • Oncotype Dx
  • Research
  • Science
  • Science (multidisciplinary)
ispartof: SpringerPlus, 2015-01-30, Vol.4 (1), p.36-36
description: Clinicians have traditionally used clinicopathological (CP) factors to determine locoregional recurrence (LR) risk of breast cancer and have generated the IBTR! nomogram to predict the risk of ipsilateral breast tumor recurrence (IBTR). The 21-gene recurrence score (RS) assay was recently correlated with LR in retrospective studies. The objective of this study was to examine the relationship between the RS and IBTR!. CP characteristics of 308 consecutive patients who underwent RS testing at our institution were examined. IBTR! was used to estimate the risk of 10-year IBTR. Descriptive statistics were used to compare the RS with the estimated IBTR!. Given a low event rate in this cohort, actual IBTR rates were not reported. Most patients had stage I/II (98%) and grade I/II (77%) disease. Median age was 54 years (range, 30–78). Median IBTR! without radiation therapy was 10% (mean, 12% [range, 4-43%]). RS was low (30) in 52% (n = 160), 40% (n = 123), and 8% (n = 25) patients. Overall, IBTR! did not correlate with RS ( P  = .77). We saw no correlation between RS and IBTR! in patients with less than ( P  = .32) or greater than ( P  = .48) a 10% risk of IBTR. Interestingly, Ki-67 expression correlated with both IBTR! ( P  = .019) and the RS ( P  = .002). Further study is warranted to determine if the RS can provide complementary biological information to CP factors in estimating the risk of LR. Prospective studies evaluating this association may potentially allow for individualized treatment decisions.
language: eng
source:
identifier: ISSN: 2193-1801
fulltext: no_fulltext
issn:
  • 2193-1801
  • 2193-1801
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.3263395
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_pubme
recordidTN_cdi_crossref_primary_10_1186_s40064_015_0840_y
sourceformatXML
sourcesystemPC
sourcerecordid1655258447
originalsourceidFETCH-LOGICAL-1579t-d232044fedccf3cad923d60aefbc7a748feada412424c26517e31c4bd2ffea020
addsrcrecordideNqFksFu1DAQhiMEotXSB-CCjLhwqMF2nDi5IEG10EoVSNVythx7spsqsYPtFO1r9InrKKXaVgJ8iaX5_y-emT_LXlPygdKq_Bg4ISXHhBaYVJzg_bPsmNE6x7Qi9PnB_Sg7CeGapFMKygV5mR2xohSc1-VxdrvZAWIUb8EC8qAn78FqQEE7D0i7YexhABsDuviyuXqL1iF2g4oQUGcRKN_vcYhqC6do5_zgFgiM0Xk8utDF7iaVztdXDNtUV_0p6vfDuEPWGcAWtmpWoMaDChFplX7tX2UvWtUHOLn_rrKfX9ebs3N8-ePbxdnnS0wLUUdsWM4I5y0YrdtcK1Oz3JREQdtooQSvWlBGcco445qVBRWQU80bw9pUIYyssk8Ld5yaIVFSl171cvSpQb-XTnXyccV2O7l1N5LntKpYmQDfF4AbwarOwyOvsRClATON8ncrCaHSFIaAEkK3RLGGCN2YJlekLgTNTVvyBHx__yLvfk0Qohy6oKHvlQU3BZnWXuUkr4v6_9KyKFhR8bTvVfbuifTaTd6m0c7AkiZkNU-DLirtXQge2odmKJFz4OQSOJkCJ-fAyX3yvDmc4IPjT7ySQDyB6i6mlbt5oF3_TzRbnCFB7Rb8waP_aroDdaD04A
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1866183082
display
typearticle
titleThe 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
creatorThaker, Nikhil G ; Hoffman, Karen E ; Stauder, Michael C ; Shaitelman, Simona F ; Strom, Eric A ; Tereffe, Welela ; Smith, Benjamin D ; Perkins, George H ; Huo, Lei ; Munsell, Mark F ; Pusztai, Lajos ; Buchholz, Thomas A ; Woodward, Wendy A
creatorcontribThaker, Nikhil G ; Hoffman, Karen E ; Stauder, Michael C ; Shaitelman, Simona F ; Strom, Eric A ; Tereffe, Welela ; Smith, Benjamin D ; Perkins, George H ; Huo, Lei ; Munsell, Mark F ; Pusztai, Lajos ; Buchholz, Thomas A ; Woodward, Wendy A
descriptionClinicians have traditionally used clinicopathological (CP) factors to determine locoregional recurrence (LR) risk of breast cancer and have generated the IBTR! nomogram to predict the risk of ipsilateral breast tumor recurrence (IBTR). The 21-gene recurrence score (RS) assay was recently correlated with LR in retrospective studies. The objective of this study was to examine the relationship between the RS and IBTR!. CP characteristics of 308 consecutive patients who underwent RS testing at our institution were examined. IBTR! was used to estimate the risk of 10-year IBTR. Descriptive statistics were used to compare the RS with the estimated IBTR!. Given a low event rate in this cohort, actual IBTR rates were not reported. Most patients had stage I/II (98%) and grade I/II (77%) disease. Median age was 54 years (range, 30–78). Median IBTR! without radiation therapy was 10% (mean, 12% [range, 4-43%]). RS was low (<18), intermediate (18–30), and high (>30) in 52% (n = 160), 40% (n = 123), and 8% (n = 25) patients. Overall, IBTR! did not correlate with RS ( P  = .77). We saw no correlation between RS and IBTR! in patients with less than ( P  = .32) or greater than ( P  = .48) a 10% risk of IBTR. Interestingly, Ki-67 expression correlated with both IBTR! ( P  = .019) and the RS ( P  = .002). Further study is warranted to determine if the RS can provide complementary biological information to CP factors in estimating the risk of LR. Prospective studies evaluating this association may potentially allow for individualized treatment decisions.
identifier
0ISSN: 2193-1801
1EISSN: 2193-1801
2DOI: 10.1186/s40064-015-0840-y
3PMID: 25674496
languageeng
publisherCham: Springer International Publishing
subject21-gene recurrence score ; Breast Cancer ; gene recurrence score ; Humanities and Social Sciences ; IBTR ; Ipsilateral breast tumor recurrence ; Local recurrence ; Medicine ; Molecular profiling ; multidisciplinary ; Oncotype Dx ; Research ; Science ; Science (multidisciplinary)
ispartofSpringerPlus, 2015-01-30, Vol.4 (1), p.36-36
rights
0Thaker et al.; licensee Springer. 2015. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
1Thaker et al.; licensee Springer. 2015
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1579t-d232044fedccf3cad923d60aefbc7a748feada412424c26517e31c4bd2ffea020
citesFETCH-LOGICAL-1579t-d232044fedccf3cad923d60aefbc7a748feada412424c26517e31c4bd2ffea020
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25674496$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Thaker, Nikhil G
1Hoffman, Karen E
2Stauder, Michael C
3Shaitelman, Simona F
4Strom, Eric A
5Tereffe, Welela
6Smith, Benjamin D
7Perkins, George H
8Huo, Lei
9Munsell, Mark F
10Pusztai, Lajos
11Buchholz, Thomas A
12Woodward, Wendy A
title
0The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
1SpringerPlus
addtitle
0SpringerPlus
1Springerplus
descriptionClinicians have traditionally used clinicopathological (CP) factors to determine locoregional recurrence (LR) risk of breast cancer and have generated the IBTR! nomogram to predict the risk of ipsilateral breast tumor recurrence (IBTR). The 21-gene recurrence score (RS) assay was recently correlated with LR in retrospective studies. The objective of this study was to examine the relationship between the RS and IBTR!. CP characteristics of 308 consecutive patients who underwent RS testing at our institution were examined. IBTR! was used to estimate the risk of 10-year IBTR. Descriptive statistics were used to compare the RS with the estimated IBTR!. Given a low event rate in this cohort, actual IBTR rates were not reported. Most patients had stage I/II (98%) and grade I/II (77%) disease. Median age was 54 years (range, 30–78). Median IBTR! without radiation therapy was 10% (mean, 12% [range, 4-43%]). RS was low (<18), intermediate (18–30), and high (>30) in 52% (n = 160), 40% (n = 123), and 8% (n = 25) patients. Overall, IBTR! did not correlate with RS ( P  = .77). We saw no correlation between RS and IBTR! in patients with less than ( P  = .32) or greater than ( P  = .48) a 10% risk of IBTR. Interestingly, Ki-67 expression correlated with both IBTR! ( P  = .019) and the RS ( P  = .002). Further study is warranted to determine if the RS can provide complementary biological information to CP factors in estimating the risk of LR. Prospective studies evaluating this association may potentially allow for individualized treatment decisions.
subject
021-gene recurrence score
1Breast Cancer
2gene recurrence score
3Humanities and Social Sciences
4IBTR
5Ipsilateral breast tumor recurrence
6Local recurrence
7Medicine
8Molecular profiling
9multidisciplinary
10Oncotype Dx
11Research
12Science
13Science (multidisciplinary)
issn
02193-1801
12193-1801
fulltextfalse
rsrctypearticle
creationdate2015
recordtypearticle
recordideNqFksFu1DAQhiMEotXSB-CCjLhwqMF2nDi5IEG10EoVSNVythx7spsqsYPtFO1r9InrKKXaVgJ8iaX5_y-emT_LXlPygdKq_Bg4ISXHhBaYVJzg_bPsmNE6x7Qi9PnB_Sg7CeGapFMKygV5mR2xohSc1-VxdrvZAWIUb8EC8qAn78FqQEE7D0i7YexhABsDuviyuXqL1iF2g4oQUGcRKN_vcYhqC6do5_zgFgiM0Xk8utDF7iaVztdXDNtUV_0p6vfDuEPWGcAWtmpWoMaDChFplX7tX2UvWtUHOLn_rrKfX9ebs3N8-ePbxdnnS0wLUUdsWM4I5y0YrdtcK1Oz3JREQdtooQSvWlBGcco445qVBRWQU80bw9pUIYyssk8Ld5yaIVFSl171cvSpQb-XTnXyccV2O7l1N5LntKpYmQDfF4AbwarOwyOvsRClATON8ncrCaHSFIaAEkK3RLGGCN2YJlekLgTNTVvyBHx__yLvfk0Qohy6oKHvlQU3BZnWXuUkr4v6_9KyKFhR8bTvVfbuifTaTd6m0c7AkiZkNU-DLirtXQge2odmKJFz4OQSOJkCJ-fAyX3yvDmc4IPjT7ySQDyB6i6mlbt5oF3_TzRbnCFB7Rb8waP_aroDdaD04A
startdate20150130
enddate20150130
creator
0Thaker, Nikhil G
1Hoffman, Karen E
2Stauder, Michael C
3Shaitelman, Simona F
4Strom, Eric A
5Tereffe, Welela
6Smith, Benjamin D
7Perkins, George H
8Huo, Lei
9Munsell, Mark F
10Pusztai, Lajos
11Buchholz, Thomas A
12Woodward, Wendy A
general
0Springer International Publishing
1Springer Nature B.V
scope
0NPM
1AAYXX
2CITATION
33V.
47X2
57XC
68CJ
78FE
88FG
98FH
108FK
11ABJCF
12ARAPS
13ATCPS
14AZQEC
15BBNVY
16BENPR
17BGLVJ
18BHPHI
19BKSAR
20C17
21CZ9
22D1I
23D1J
24D1K
25DWQXO
26GNUQQ
27HCIFZ
28JQ2
29K6-
30K7-
31KB.
32KC.
33L6V
34LA8
35LK5
36LK8
37M0K
38M7P
39M7R
40M7S
41P5Z
42P62
43PATMY
44PCBAR
45PDBOC
46PQEST
47PQQKQ
48PQUKI
49PTHSS
50PYCSY
517X8
527QO
538FD
54FR3
55P64
56RC3
57BOBZL
58CLFQK
595PM
sort
creationdate20150130
titleThe 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
authorThaker, Nikhil G ; Hoffman, Karen E ; Stauder, Michael C ; Shaitelman, Simona F ; Strom, Eric A ; Tereffe, Welela ; Smith, Benjamin D ; Perkins, George H ; Huo, Lei ; Munsell, Mark F ; Pusztai, Lajos ; Buchholz, Thomas A ; Woodward, Wendy A
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1579t-d232044fedccf3cad923d60aefbc7a748feada412424c26517e31c4bd2ffea020
rsrctypearticles
prefilterarticles
languageeng
creationdate2015
topic
021-gene recurrence score
1Breast Cancer
2gene recurrence score
3Humanities and Social Sciences
4IBTR
5Ipsilateral breast tumor recurrence
6Local recurrence
7Medicine
8Molecular profiling
9multidisciplinary
10Oncotype Dx
11Research
12Science
13Science (multidisciplinary)
toplevelpeer_reviewed
creatorcontrib
0Thaker, Nikhil G
1Hoffman, Karen E
2Stauder, Michael C
3Shaitelman, Simona F
4Strom, Eric A
5Tereffe, Welela
6Smith, Benjamin D
7Perkins, George H
8Huo, Lei
9Munsell, Mark F
10Pusztai, Lajos
11Buchholz, Thomas A
12Woodward, Wendy A
collection
0PubMed
1CrossRef
2ProQuest Central (Corporate)
3Agricultural Science Collection
4ProQuest Environmental Science Journals
5ProQuest Aquatic Science Journals
6ProQuest SciTech Collection
7ProQuest Technology Collection
8ProQuest Natural Science Collection
9ProQuest Central (Alumni) (purchase pre-March 2016)
10Materials Science & Engineering Collection
11Advanced Technologies & Aerospace Collection
12Agricultural & Environmental Science Collection
13ProQuest Central Essentials
14Biological Science Collection
15ProQuest Central
16Technology Collection
17Natural Science Collection
18Earth, Atmospheric & Aquatic Science Collection
19Proquest Polymer Science Collection
20ProQuest Polymer Science Collection
21ProQuest Materials Science Collection
22ProQuest Aquatic Science Collection
23ProQuest Atmospheric Science Collection
24ProQuest Central Korea
25ProQuest Central Student
26SciTech Premium Collection
27ProQuest Computer Science Collection
28ProQuest Atmospheric Science Journals
29Computer Science Database
30Materials Science Database
31ProQuest Polymer Science Journals - DO NOT USE
32ProQuest Engineering Collection
33ProQuest Environmental Science Collection
34ProQuest Earth Science Collection
35ProQuest Biological Science Collection
36Agricultural Science Database
37Biological Science Database
38ProQuest Earth Science Journals
39Engineering Database
40Advanced Technologies & Aerospace Database
41ProQuest Advanced Technologies & Aerospace Collection
42Environmental Science Database
43Earth, Atmospheric & Aquatic Science Database
44Materials Science Collection
45ProQuest One Academic Eastern Edition
46ProQuest One Academic
47ProQuest One Academic UKI Edition
48Engineering Collection
49Environmental Science Collection
50MEDLINE - Academic
51Biotechnology Research Abstracts
52Technology Research Database
53Engineering Research Database
54Biotechnology and BioEngineering Abstracts
55Genetics Abstracts
56OpenAIRE (Open Access)
57OpenAIRE
58PubMed Central (Full Participant titles)
jtitleSpringerPlus
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Thaker, Nikhil G
1Hoffman, Karen E
2Stauder, Michael C
3Shaitelman, Simona F
4Strom, Eric A
5Tereffe, Welela
6Smith, Benjamin D
7Perkins, George H
8Huo, Lei
9Munsell, Mark F
10Pusztai, Lajos
11Buchholz, Thomas A
12Woodward, Wendy A
formatjournal
genrearticle
ristypeJOUR
atitleThe 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer
jtitleSpringerPlus
stitleSpringerPlus
addtitleSpringerplus
date2015-01-30
risdate2015
volume4
issue1
spage36
epage36
pages36-36
issn2193-1801
eissn2193-1801
abstractClinicians have traditionally used clinicopathological (CP) factors to determine locoregional recurrence (LR) risk of breast cancer and have generated the IBTR! nomogram to predict the risk of ipsilateral breast tumor recurrence (IBTR). The 21-gene recurrence score (RS) assay was recently correlated with LR in retrospective studies. The objective of this study was to examine the relationship between the RS and IBTR!. CP characteristics of 308 consecutive patients who underwent RS testing at our institution were examined. IBTR! was used to estimate the risk of 10-year IBTR. Descriptive statistics were used to compare the RS with the estimated IBTR!. Given a low event rate in this cohort, actual IBTR rates were not reported. Most patients had stage I/II (98%) and grade I/II (77%) disease. Median age was 54 years (range, 30–78). Median IBTR! without radiation therapy was 10% (mean, 12% [range, 4-43%]). RS was low (<18), intermediate (18–30), and high (>30) in 52% (n = 160), 40% (n = 123), and 8% (n = 25) patients. Overall, IBTR! did not correlate with RS ( P  = .77). We saw no correlation between RS and IBTR! in patients with less than ( P  = .32) or greater than ( P  = .48) a 10% risk of IBTR. Interestingly, Ki-67 expression correlated with both IBTR! ( P  = .019) and the RS ( P  = .002). Further study is warranted to determine if the RS can provide complementary biological information to CP factors in estimating the risk of LR. Prospective studies evaluating this association may potentially allow for individualized treatment decisions.
copCham
pubSpringer International Publishing
pmid25674496
doi10.1186/s40064-015-0840-y
oafree_for_read